{"id":"W4379328597","doi":"10.1200/jco.2023.41.16_suppl.tps620","title":"A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; University of Toronto; Toronto General Hospital; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; St Mary's Hospital Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Neratinib; Medicine; Oncology; Internal medicine; Trastuzumab emtansine; Lapatinib; Trastuzumab; Breast cancer; Clinical endpoint; Minimal residual disease; Adjuvant; Adjuvant therapy; Cancer; Clinical trial; Leukemia","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002433307,0.002829161,0.00236617,0.0005517364,0.0006117419,0.001649438,0.001824656,0.002957562,0.008220905],"category_scores_gemma":[0.001983509,0.001020977,0.001628666,0.0003958566,0.00188854,0.002547178,0.0006703649,0.00626244,0.002418674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001520821,"about_ca_system_score_gemma":0.001915422,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000836278,"about_ca_topic_score_gemma":0.002609491,"domain_scores_codex":[0.9991549,0.0003672834,0.00003526628,0.0001917246,0.00006783675,0.0001828945],"domain_scores_gemma":[0.9983636,0.0002483821,0.0002829871,0.0001677604,0.00009912697,0.0008381329],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.93086,0.04218493,0.0008905572,0.0004279302,0.0006329584,0.0001039285,0.0001378572,0.0008126661,0.006318562,0.0002234325,0.002189378,0.01521778],"study_design_scores_gemma":[0.8546315,0.1417342,0.001309686,0.00001520707,0.000119619,0.00008506997,0.00003133557,0.0003962187,0.0004556352,0.0002346833,0.0009707956,0.00001601852],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9766285,0.002441633,0.001141839,0.001566476,0.0006851745,0.009816465,0.003147042,0.0002335733,0.004339335],"genre_scores_gemma":[0.9729736,0.001511697,0.00266139,0.002139527,0.0004184108,0.01005053,0.004246559,0.00005771558,0.005940519],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008220905,"threshold_uncertainty_score":0.0275017,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08444538164440572,"score_gpt":0.4499091666000617,"score_spread":0.365463784955656,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}